On May 19, 2023 the U.S. Food and Drug Administration (FDA) announced it has approved epcoritamab-bysp (Epkinly, co-developed by Genmab and AbbVie) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
“The approval of epcoritamab-bysp demonstrates the significant progress being made in the treatment of relapsed/refractory DLBCL,” said Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation. “New treatment options bring with them new hope for the lymphoma community.”
For more information on the FDA approval of epcoritamab-bysp (Epkinly, Genmab US, Inc.), visit the FDA’s website. To learn more about treatment options for DLBCL, visit the DLBCL learning center.